Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
The LANCET Trial: Lantus for CRP Reduction in Early Type 2 Diabetes
NCT00366301Phase 4Terminated
- Sponsor
- Brigham and Women's Hospital
- Start
- Aug 2006
- Primary completion
- Apr 2009
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 4 trial of insulin glargine in type 2 diabetes mellitus (T2DM), sponsored by Brigham and Women's Hospital. Started Aug 2006; status: terminated.
02
Drugs
insulin glargine
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00366301.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00366301.